期刊
ANALYST
卷 133, 期 11, 页码 1550-1555出版社
ROYAL SOC CHEMISTRY
DOI: 10.1039/b719810h
关键词
-
资金
- National Institutes of Health CounterACT Program
- National Institute of Neurological Disorders and Stroke [NS058161-01]
- LDRD program at Pacific Northwest National Laboratory (PNNL)
- U.S. Department of Energy (DOE)
- Battelle for DOE [DE-AC05-76RL01830]
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [U01NS058161] Funding Source: NIH RePORTER
We report a dye-encapsulated silica nanoparticle as a label, with the advantages of high fluorescence intensity, photostability, and biocompatibility, in conjunction with microarray technology for sensitive immunoassay of a biomarker, interleukin-6 (IL-6), on a microarray format. The tris(2,2'-bipyridyl) ruthenium(II) chloride hexahydrate (Rubpy) dye was incorporated into silica nanoparticles using a simple one-step microemulsion synthesis. In this synthesis process, Igepal CA520 was used as the surfactant, therefore, no requirement of cosolvent during the synthesis and the particle size was reduced comparing to the commonly used Triton surfactant system. The nanoparticles are uniform in size with a diameter of 50 nm. The microarray fluorescent immunoassay approach based on dye-doped silica nanoparticle labels has high sensitivity for practical applications with a limit of detection for IL-6 down to 0.1 ng mL(-1). The calibration curve is linear over the range from 0.1 ng mL(-1) to 10 ng mL(-1). Furthermore, results illustrated that the assay is highly specific for IL-6 in the presence of range of cytokines or proteins. The RuDS dye-labeled nanoparticles in connection with protein microarrays show the promise for clinical diagnosis of biomarkers.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据